Company Profile · Medtech
Capstan Medical
A robot, a catheter, and a new heart valve - aimed at the one organ that refuses to hold still.
A robot, a catheter, and a new heart valve - aimed at the one organ that refuses to hold still.
In an operating room, a surgeon threads a folded heart valve up through a blood vessel, steers it into a chamber that contracts roughly once a second, and lets go at exactly the right instant. The hands doing the steering are not entirely human. They are guided by a robot built by Capstan Medical.
Capstan Medical is a 85-person company in Santa Cruz, California that has done something the structural heart field had not: it used a robot to deliver and place a replacement mitral valve through a catheter, in a living person, twice. No sternum sawed open. No heart-lung machine. A wire, an implant, and software steady enough to thread a needle that keeps moving.
The company sells nothing yet. Its products carry the polite disclaimer "for clinical investigation only." And yet it has raised more than $140 million from investors who are not known for sentimentality. That gap - between zero revenue and nine figures of conviction - is the whole story.
Consider the mitral valve. When it fails to close - a condition called mitral regurgitation - blood sloshes backward with every beat, and the heart slowly wears itself out trying to compensate. It is one of the most common valve disorders. It is also one of the hardest to fix.
Open-heart surgery works, but it asks a lot of a patient: a cracked sternum, a stopped heart, weeks of recovery. Plenty of the people who need it most - older, sicker, frailer - are precisely the people least able to survive it. So they don't get it. They get managed, and then they get worse.
Transcatheter techniques, the kind that fixed the aortic valve revolution, promised a gentler route: deliver the implant through a vessel instead of an incision. But the mitral and tricuspid valves are bigger, oddly shaped, and sit in chambers that move in three dimensions. Delivering a device there by hand is, charitably, difficult. The catheter has to bend, rotate, and hold position against a tide of blood while a human wrist fights physics.
Translation: imagine parking a car, through a keyhole, while the garage does jumping jacks.
Capstan Medical was founded in 2020 inside Occam Labs, a Santa Cruz incubator, by Dan Wallace and a founding team that had spent careers in exactly the two worlds the problem demanded: cardiac implants and surgical robotics. CEO Maggie Nixon spent more than two decades at Intuitive Surgical, the company behind the da Vinci robot. She and Wallace had worked together since around 2000.
Their bet was unfashionably specific. Don't build a better valve and hope a surgeon's hand can place it. Don't build a robot and hope someone makes a compatible implant. Build all three - the implant, the catheter, and the robotic delivery platform - as one system, designed together from the start.
The name is a tell. A capstan is the rotating drum on a ship that sailors use to wind rope and apply steady, controlled force. Not brute strength. Controlled force. For a company whose entire value proposition is steadiness inside a moving target, it is an almost suspiciously good metaphor.
Founder. Decades in startup and commercial medical technology, with deep roots in cardiac device development.
CEO. 20+ years at Intuitive Surgical; brought the surgical-robotics playbook to structural heart.
Heads of Robotics, Implants, Delivery Systems, Regulatory, and Quality - many alumni of the surgical-robotics world.
Capstan's system has three parts that travel together. A next-generation implant that collapses small enough to fit through a vessel and expands into place. A steerable catheter that carries it. And a robotic delivery platform - described as the first of its kind for this application - that does the bending, rotating, and precise positioning a human wrist struggles to sustain.
The first target is mitral valve regurgitation. The second is the tricuspid valve, another notoriously awkward repair, and the elegant part is that it runs on the same robotic platform. Build the hard machine once; aim it at more than one problem. That is how a 85-person company punches above its weight.
Same robot, different valve. The medtech equivalent of one charger that finally fits every device.
Capstan Medical spins out of a Santa Cruz incubator, pairing cardiac-device and surgical-robotics veterans.
Funding from backers including Intuitive Ventures and Yu Galaxy; company goes public with its robotics-plus-implant approach.
Oversubscribed round led by Eclipse pushes total funding past $140M, ahead of first-in-human work.
Two patients receive robot-assisted transcatheter mitral valve replacements - a first in structural heart disease.
Tricuspid program advances into full development on the same platform; pivotal-trial timing targeted.
It is easy to raise money on a pitch deck. It is harder to raise an oversubscribed $110 million round the same month you head into first-in-human procedures. Capstan did both. The December 2024 Series C was led by Eclipse, with repeat checks from Intuitive Ventures and Yu Galaxy and a new investment from Gideon Strategic Partners.
The Intuitive Ventures connection is not a coincidence. It is the venture arm of Intuitive Surgical, the company that made surgical robotics a standard of care. When the people who built the da Vinci robot keep funding your beating-heart robot, that is a particular kind of endorsement.
USD raised · cumulative total now exceeds $140M
Bars scaled to the Series C round. Figures from public funding announcements.
The recognition followed. Santa Cruz Works named Capstan a regional "Titan" for the pioneering procedure. For a company that is still pre-commercial, the scoreboard reads: a working platform, a first-of-its-kind human result, and investors who keep coming back.
Capstan describes its goal as elegant, effective solutions for unmet clinical needs, with patients first. That phrasing could be wallpaper at any medtech company. What gives it weight here is who the technology is for: the people currently turned away from open-heart surgery because the surgery itself might kill them.
If a robot-guided catheter can place a valve without cracking a chest, the population that qualifies for treatment widens. That is the entire point. Not a better experience for patients who already had options - a first option for patients who had none.
Return to that operating room. The surgeon threads a folded valve up a vessel toward a chamber that contracts once a second. The difference Capstan is chasing is not drama - it is the absence of it. No saw. No stopped heart. No weeks of recovery for a patient who might not have weeks to spare.
The work is not finished. Pivotal trials and FDA clearance stand between Capstan and a product anyone can buy, and plenty of medtech companies have died on exactly that road. But the hardest question - can a robot place a valve inside a beating human heart? - now has a two-patient answer. And the answer was yes.
Heart valve disease is common, deadly, and undertreated. Capstan Medical did not set out to make it rare. It set out to make it reachable. The steadiest hand in the room, it turns out, may not be a hand at all.